Organovo (NASDAQ:ONVO – Get Free Report) posted its quarterly earnings data on Wednesday. The medical research company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.02, Zacks reports. Organovo had a negative net margin of 12,176.70% and a negative return on equity of 249.28%.
Organovo Stock Performance
Shares of NASDAQ ONVO opened at $0.38 on Thursday. The company’s 50 day simple moving average is $0.38 and its 200 day simple moving average is $0.45. Organovo has a fifty-two week low of $0.32 and a fifty-two week high of $1.74.
Analyst Upgrades and Downgrades
Separately, StockNews.com began coverage on Organovo in a research report on Saturday, February 15th. They set a “sell” rating for the company.
Organovo Company Profile
Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
Further Reading
- Five stocks we like better than Organovo
- 3 Best Fintech Stocks for a Portfolio Boost
- Hershey’s Sweet Comeback: Why Investors Are Taking Notice
- Insider Selling Explained: Can it Inform Your Investing Choices?
- 3 Reasons Occidental Petroleum Will Gush Higher in 2025
- Market Cap Calculator: How to Calculate Market Cap
- After Earnings, Is Transocean Stock the Best Energy Play?
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.
